- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | William Blair reiterates Outperform on Tenaya Therapeutics stock | 15 | Investing.com | ||
| 12.03. | Leerink Partners reiterates Outperform on Tenaya stock at $2 | 10 | Investing.com | ||
| 11.03. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 190 | GlobeNewswire (Europe) | Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports... ► Artikel lesen | |
| 09.03. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy | 15 | GlobeNewswire (USA) | ||
| 06.03. | Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs | 11 | BioPharma Dive | ||
| 06.03. | Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal | 6 | Pharmaceutical Technology | ||
| 06.03. | Alnylam bets on Tenaya RNAi tech, and other licensing news | 4 | pharmaphorum | ||
| TENAYA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.03. | Tenaya Therapeutics Stock Jumps After New Alnylam Deal | 11 | Benzinga.com | ||
| 05.03. | Tenaya, Alnylam ink research collab to find gene targets for cardio drugs | 3 | FierceBiotech | ||
| 05.03. | Tenaya Enters Research Collaboration With Alnylam; To Receive Up To $10 Mln In Upfront Payments | 636 | AFX News | WASHINGTON (dpa-AFX) - Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY), to discover human genetic targets for the potential development... ► Artikel lesen | |
| 05.03. | Alnylam's research pact worth up to $1.1B sends Tenaya higher | 5 | Seeking Alpha | ||
| 05.03. | Tenaya, Alnylam partner on heart disease gene targets | 5 | Investing.com | ||
| 05.03. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.02. | Tenaya Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 8 | SEC Filings | ||
| 30.01. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.01. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones | 1.088 | GlobeNewswire (Europe) | Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK-1 Trial of Adults with MYBPC3-Associated HCM Expects to... ► Artikel lesen | |
| 02.01. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.25 | Tenaya Therapeutics: Canaccord senkt Kursziel auf 5 US-Dollar, bestätigt aber 'Buy'-Rating | 21 | Investing.com Deutsch | ||
| 18.12.25 | Tenaya Therapeutics stock price target lowered to $5 at Canaccord | 5 | Investing.com | ||
| 12.12.25 | Tenaya Stock Plunges After $60 Million Equity Offering | 8 | Benzinga.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,30 | -0,32 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| MODERNA | 43,895 | +0,15 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| VALNEVA | 2,692 | +3,30 % | BRANDMELDUNG bei Valneva: 1,7% Plus und das könnte erst der Anfang sein - Was das für Ihr Depot bedeutet | ||
| AMGEN | 303,95 | +0,03 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 7,310 | +0,27 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 152,00 | +0,45 % | Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,475 | +0,58 % | Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM | ||
| OCUGEN | 1,602 | -0,62 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,930 | +2,14 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| BIONXT SOLUTIONS | 0,321 | +1,90 % | BioNxt sichert sich einheitliches europäisches Patent für seine sublinguale Cladribin-ODF-Plattform in 18 Ländern | VANCOUVER, BC / ACCESS Newswire / 7. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives Biowissenschaftsunternehmen, das
sich... ► Artikel lesen | |
| MAINZ BIOMED | 0,473 | 0,00 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| VIKING THERAPEUTICS | 30,000 | +0,50 % | Where Will Viking Therapeutics Stock Be in 10 Years? | ||
| INTELLIA THERAPEUTICS | 11,620 | -1,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 39,000 | +3,35 % | Trader-Interview mit Sascha Huber: Marvell Technology, Intuit, Salesforce, Tempus AI & MicroStrategy | In dieser Ausgabe des Trader-Interviews analysieren Andreas Bernstein und Sascha Huber die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit Fokus auf den Einfluss von Künstlicher Intelligenz... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,396 | -0,64 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen |
Das Unternehmen TENAYA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,733 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TENAYA THERAPEUTICS INC finden Sie auf Wallstreet Online.